nutrafoods-international-journal-logo-80nutrafoods-international-journal-logo-80nutrafoods-international-journal-logo-80nutrafoods-international-journal-logo-80
  • HOME
  • NUTRAFOODS BOARD
  • ARTICLES
  • SUBMIT A MANUSCRIPT
  • CHECK STATUS

Bacterial therapy to help eradicate Helicobacter pylori and to reduce the gastrointestinal side effects of antibiotics: a possible treatment scheme?

Helicobacter pylori (Fig. 1), previously called Campylobacter pylori, is a gram-negative, microaerophilic bacterium found usually in the stomach. It was identified in 1982 by two Australian who found it in a patient with chronic gastritis and gastric ulcers, conditions not previously thought to have a bacterial aetiology. H. pylori is also linked to the development of duodenal ulcers and stomach cancer. It is present in the stomach of 50% of the world’s population and asymptomatic in over 80% of those infected. The standard first-line therapy to eradicate H. pylori, is the so-called triple therapy consisting of proton pump inhibitors (PPI), mainly omeprazole, along with the antibiotics clarithromycin and amoxicillin. Variations on the triple therapy have been developed over the years, using a different PPI, or replacing amoxicillin with metronidazole for those with an allergy to penicillin. Due to antibiotic-resistant bacteria, an additional round of antibiotic therapy, the quadruple therapy, consisting of a PPI, a bismuth colloid, metronidazole and tetracyclines, has been developed.

DOI: 10.17470/NF-017-0001-4

DATE: 2017

AUTHOR/S: Di Pierro F

ABSTRACT:
Helicobacter pylori (Fig. 1), previously called Campylobacter pylori, is a gram-negative, microaerophilic bacterium found usually in the stomach. It was identified in 1982 by two Australian who found it in a patient with chronic gastritis and gastric ulcers, conditions not previously thought to have a bacterial aetiology. H. pylori is also linked to the development of duodenal ulcers and stomach cancer. It is present in the stomach of 50% of the world’s population and asymptomatic in over 80% of those infected. The standard first-line therapy to eradicate H. pylori, is the so-called triple therapy consisting of proton pump inhibitors (PPI), mainly omeprazole, along with the antibiotics clarithromycin and amoxicillin. Variations on the triple therapy have been developed over the years, using a different PPI, or replacing amoxicillin with metronidazole for those with an allergy to penicillin. Due to antibiotic-resistant bacteria, an additional round of antibiotic therapy, the quadruple therapy, consisting of a PPI, a bismuth colloid, metronidazole and tetracyclines, has been developed.

KEYWORDS:
Bifibacterium animalis subspecies lactis BB12, Enterococcus faecium L3, Hydrogen producing bacteria

 

10.17470/NF-017-0001-4

Download Article

Find a Specific Article

Find by Year

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016


ISSN 2240-5291 (electronic edition)

EDITORIAL INFORMATION

Editor-in-Chief
Francesco Di Pierro

Journal Office
Anna Lebovich

Mail: info@nutrafoods.eu

Copyright 2019 – Nutrafoods.eu

International Journal on Nutraceuticals, Functional Foods and Novel Foods
- from Research to Industrial Applications -


Privacy Policy  |  Cookies Policy
WebMaster KosmoSol
 
      By continuing to browse the site you are agreeing to our use of cookies.